Effect of intracerebroventricular continuous infusion of valproic acid versus single i.p. and i.c.v. injections in the amygdala kindling epilepsy model

Epilepsy Research

Volumn 70, Issue 1, 2006, Pages 15-26

  Serralta, Alfonso ^a   Barcia, Juan A ^b,c   Ortiz, Pedro ^b   Durán, Carmen ^b   Hernández, M Eugenia ^b,c   Alós, Manuel ^d  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^c CENTRO DE INVESTIGACIÓN PRÍNCIPE FELIPE   (Spain)

^d HOSPITAL GENERAL DE CASTELLÓN   (Spain)

Author keywords

Acute injection; Continuous infusion; Epilepsy; Intracerebroventricular route; Kindling; Valproic acid

Indexed keywords

ANTICONVULSIVE AGENT; VALPROIC ACID;

AFTERDISCHARGE; AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; ATAXIA; BRAIN; CATHETER; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE DURATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG LIVER LEVEL; EPILEPSY; FOCAL EPILEPSY; IMMUNOFLUORESCENCE; KINDLING; LATENT PERIOD; MALE; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; RAT; RAT STRAIN; SEDATION; SEIZURE THRESHOLD;

AMYGDALA; ANIMALS; ANTICONVULSANTS; CEREBRAL VENTRICLES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EPILEPSY; INFUSIONS, PARENTERAL; INJECTIONS, INTRAVENTRICULAR; KINDLING, NEUROLOGIC; MALE; RATS; RATS, WISTAR; VALPROIC ACID;

EID: 33745395777     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2006.02.003     Document Type: Article

References (41)

1. Albertson T., Peterson S., and Stark L. Anticonvulsant drugs and their antagonism of kindled amygdaloid seizures in rats. Neuropharmacology 19 (1980) 643-652
2. Albright P., and Burnham W. Development of a new pharmacological seizure model: effects of anticonvulsants on cortical- and amygdala-kindled seizures in the rat. Epilepsia 21 (1980) 681-689
3. Ballantyne J.C., and Carwood C.M. Comparative efficacy of epidural, subarachnoid, and intracerebroventricular opioids in patients with pain due to cancer. Cochrane Database System Review 25 1 (2005) CD005178
4. Barcia J.A., Rubio P., Alos M., Serralta A., and Belda V. Anticonvulsant and neurotoxic effects of intracerebroventricular injection of phenytoin, phenobarbital and carbamazepine in an amygdala-kindling model of epilepsy in the rat. Epilepsy Research 33 2-3 (1999) 159-167
5. Blasberg R.G., Patlak C., and Shapiro W.R. Distribution of methotrexate in cerebrospinal fluid and brain after intraventricular administration. Cancer Treatment Report 61 (1977) 633-641
6. Bryant A.R., and Dreifuss F. Valproic acid hepatic fatalities. III. U.S. experience since 1986. Neurology 46 (1996) 465-469
7. Cotariu D., Reif R., Zaidman J., and Evans S. Biochemical and morphological changes induced by sodium valproate in rat liver. Pharmacology and Toxicology 60 (1987) 235-236
8. Croucher M., Meldrum B., and Krogsgaard-Larsen P. Anticonvulsant activity of GABA uptake inhibitors and their prodrugs following central or systemic administration. European Journal of Pharmacology 89 (1983) 217-228
9. Fleischhack G., Jaehde U., and Bode U. Pharmacokinetics following intraventricular administration of chemotherapy in patients with neoplastic meningitis. Clinical Pharmacokinetics 44 1 (2005) 1-31
10. Freeman F.G., and Jarvis M.F. The effect of interstimulation interval on the assessment and stability of kindled seizure thresholds. Brain Research Bulletin 7 (1981) 629-633
11. Gonsalves S., Twitchell B., Harbaugh R., Krogsgaard-Larsen P., and Schousboe A. Anticonvulsant activity of intracerebroventricularly administered glial GABA uptake inhibitors and other GABAmimetics in chemical seizure models. Epilepsy Research 4 (1989) 34-41
12. González-Darder J., and García-Teno M. Anticonvulsant effect of intraventricular antiepileptic drugs. Experimental study. Neurology Research 17 (1995) 190-192
13. Grillo M.P., Chiellini G., Tonelli M., and Benet L.Z. Effect of alpha-fluorination of valproic acid on valproyl-Sacyl-CoA formation in vivo in rats. Drug Metabolism and Disposition 29 (2001) 1210-1215
14. Harada C., Hirai T., Fujii Y., Harusawa S., Kurihara T., and Kamei C. Intracerebroventricular administration of histamine H3 receptor antagonists decreases seizures in rat models of epilepsia. Methods and Finding in Experimental and Clinical Pharmacology 26 4 (2004) 263-270
15. Harbaugh R.E. Intracranial drug administration in Alzheimer's disease. Psychopharmacol Bulletin 22 (1986) 106-109
16. Jolley M.E. Fluorescence polarization immunoassay for determination of therapeutic drug levels in human plasma. Journal of Analytical Toxicology 5 (1981) 236-240
17. Kultima K., Nystrom A.M., Scholz B., Gustafson A.L., Dencker L., and Stigson M. Valproic acid teratogenicity: a toxicogenomics approach. Environmental Health Perspectives 112 12 (2004) 1225-1235
18. Litchfield J., and Wilcoxon F. A simplified method of evaluating dose-effect experiments. Journal of Pharmacology and Experimental Therapeutics 96 (1949) 99-113
19. Lockard J., and Levy R. Valproic acid: reversibly acting drug?. Epilepsia 17 (1976) 477-479
20. Löscher W., Jâckel R., and Czuczwar S. Is amygdala kindling in rats a model for drug-resistant partial epilepsy?. Experimental Neurology 93 (1986) 211-226
21. Löscher W., Hönack D., and Hashem A. Anticonvulsant efficacy of clonazepam and the beta-carboline ZK 93423 during chronic treatment in amygdala-kindled rats. European Journal of Pharmacology 143 (1987) 403-414
22. Löscher W., Fisher J., Nau H., and Hönack D. Marked increase in anticonvulsant activity but decrease in wet-dog shake behaviour during short treatment of amygdala-kindled rats with valproic acid. European Journal of Pharmacology 150 (1988) 221-232
23. Löscher W., and Schmidt D. Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Research 2 (1988) 145-181
24. Löscher W., Fisher J., Nau H., and Hönack D. Valproic acid in amygdala-kindled rats: alterations in anticonvulsant efficacy, adverse effects and drug and metabolite levels in various brain regions during chronic treatment. Journal of Pharmacology and Experimental Therapeutics 250 (1989) 1067-1078
25. Löscher W., and Hönack D. Anticonvulsant and behavioral effects of two novel competitive N-methyl-d-aspartic acid receptor antagonists, CGP 37849 and CGP 39551, in the kindling model of epilepsy. Comparison with MK-801 and carbamazepine. Journal of Pharmacology and Experimental Therapeutics 256 (1991) 432-440
26. Löscher W., and Rundfeldt C. Kindling as a model of drug-resistant partial epilepsy: selection of phenytoin-resistant and nonresistant rats. Journal of Pharmacology and Experimental Therapeutics 258 (1991) 483-489
27. Löscher W. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs 16 (2002) 669-694
28. Mana M., Kim C., and Pinel J. Tolerance to the anticonvulsant effects of carbamazepine, diazepam, and sodium valproate in kindled rats. Pharmacology Biochemistry and Behavior 41 (1991) 109-113
29. Mana M., Kim C., Pinel J., and Jones C. Contingent tolerance to the anticonvulsant effects of carbamazepine, diazepam, and sodium valproate in kindled rats. Pharmacology Biochemistry and Behavior 41 (1991) 121-126
30. Martínez R., Vaquero J., de La Morena L., Tendillo F., and Aragonés P. Toxicology and kinetics of long-term intraventricular infusion of phenytoin and valproic acid in pigs: experimental study. Acta Neurochirurgica Supplement (Wien) 52 (1991) 3-4
31. Neuman M.G., Shear N.H., Jacobson-Brown P.M., Katz G.G., Neilson H.K., Malkiewicz I.M., Cameron R.G., and Abbot F. CYP2E1 mediated modulation of valproic acid-induced hepatotoxicity. Clinical Biochemistry 34 (2001) 211-218
32. Paxinos, G., Watson, C., 1986. The Rat Brain in Stereotactic Coordinates, Sydney.
33. Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 16 (2002) 695-714
34. Racine R. Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalography and Clinical Neurophysiology 32 (1972) 281-294
35. Raza M., Al-Bekairi A., Ageel A., and Qureshi S. Biochemical basis of sodium valproate hepatotoxicity and renal tubular disorder: time dependence of peroxidative injury. Pharmacology Research 35 (1997) 153-157
36. Rundfeldt C., Hönack D., and Löscher W. Phenytoin potently increases the threshold for focal seizures in amygdala-kindled rats. Neuropharmacology 29 (1990) 845-851
37. Seiwald M., Alesch F., and Kofler A. Intraventricular morphine administration as a treatment possibility for patients with intractable pain. Wiener Klinische Wochenschrift 108 1 (1996) 5-8
38. Sussman N., and McLain L.J. A direct hepatotoxic effect of valproic acid. Journal of the American Medical Association 242 (1979) 1173-1174
39. Wilcoxon F. Individual comparisons by ranking methods. Biometrics Bulletin 1 (1945) 80-83
40. Young N., Lewis S., Harris Q., Jarrott B., and Vajda F. The development of tolerance to the anticonvulsant effects of clonazepam, but not sodium valproate, in the amygdaloid kindled rat. Neuropharmacology 26 (1987) 1611-1614
41. Zunkeler B., Carson R.E., Olson J., Blasberg R.G., DeVroom H., Lutz R.J., Saris S.C., Wright D.C., Kammerer W., Patronas N.J., Dedrick R.L., Herscovitch P., and Oldfield E.H. Quantification and pharmacokinetics of blood-brain barrier disruption in humans. Journal of Neurosurgery 85 6 (1996) 1056-1065